Moderna says its COVID-19 vaccine generated robust immune response in children ages 6 to 11

Interim results of a Phase 2/3 trial showed Moderna’s COVID-19 vaccine was well-tolerated and generated a robust immune response in children ages 6 to 11, the company said.